|Awarded On||February 19, 2020|
|Title||Optimizing Therapeutic Strategies Against Lung Cancer Using Multimodality Imaging|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas at Dallas|
|Principal Investigator/Program Director||Li Zhang|
|Cancer Sites||Lung and Bronchus|
*Pending contract negotiation
Despite improved early detection and the use of targeted therapies and immunotherapies, the lung cancer 5-year survival rate remains 10-20% in most countries. Tumor hypoxia, i.e., oxygen deprivation, is an independent marker of poor prognosis in many types of human cancer. Substantial tumor hypoxia exists in non-small cell lung cancer (NSCLC), even in early-stage tumors. NSCLC represents 85-90% of all lung cancer cases. Importantly, recent studies in human patients and mice have shown that NSCLC tumors exhibit elevated oxidative metabolism relative to adjacent normal tissues. Our studies also showed that NSCLC cells have intensified oxygen consumption, as well as elevated synthesis and uptak...